Home / Opinion / Columns /  We must temper celebrations over the new Alzheimer’s drug

Biogen and Eisai caused a stir in September when they announced positive results in a late-stage trial for an Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data. That data arrived this week. And while it is stoking enthusiasm that physicians might soon be able to offer patients a treatment that can slow the progression of the devastating disease, doctors must balance that optimism with safety concerns and the reality that the drug is far from a cure—and it’s hard to quantify how meaningful it might be for a given patient.

The US Food and Drug Administration (FDA) appears likely to approve lecanemab early next year, capping a decades-long slog to get a drug that works, albeit modestly, by addressing one of the underlying causes of Alzheimer’s. Now comes the next slog: getting answers on still critical unknowns. Like how much will this drug meaningfully change the day-to-day lives of patients and their caregivers? Will that benefit outweigh the small risk of its more serious side effects? And will it justify the cost of what is likely to be an expensive therapy?

“Will it slow [the disease] down? Yes. Will it slow it down by an amount that probably matters to an average patient or family? Yeah, I think so," said Randall Bateman, a professor of neurology at the Washington University School of Medicine in St. Louis. “But it’s not a massive thing. It’s a modest thing. It’s important to frame it that way." Bateman is a principal investigator in a trial exploring the combination of lecanemab with a drug that targets tau, another protein that clumps together in the brains of people with Alzheimer’s disease.

Excitement about lecanemab mounted in September when Biogen and Eisai put out a press release saying that the drug, which works by clearing out the amyloid plaques that clog the brains of people with Alzheimer’s, slowed down the progression of the disease by 27%. But in a field that has had many failures and controversies—notably the disputed approval of Aduhelm, another drug from Biogen and Eisai, based not on its efficacy but its amyloid-busting abilities— some experts wanted a closer look.

Those results were unveiled Tuesday night at an Alzheimer’s conference in San Francisco. They showed that the drug powerfully lowered levels of amyloid and affirmed that 27% improvement on a test that measures factors such as memory, judgement and personal care, and benefits on secondary measures related to function and cognition.

The drug also seemed to slow the erosion of patients’ quality of life. While that is not the main consideration when the FDA considers its approval, those measurements are critically important to families, Sharon Cohen, medical director of the Toronto Memory Program, told the audience at the conference. They get at questions like how patients feel from day to day, how happy they are, and whether their caregivers are feeling burdened. The overall improvement across so many of those types of metrics demonstrates the drug “may offer meaningful benefits to patients, care partners, and society," Cohen said.

Of note, the drug’s modest benefits, whether related to cognition or quality of life, seemed to accrue over time. That makes Alzheimer’s experts hopeful that examining data well past the 18 months covered by the trial might amplify its efficacy.

But those positives might be outweighed for some by concerns about the drug’s safety. Leading into the meeting, news broke of the deaths of two participants in the lecanemab study. One, reported by Stat in October, was a man in his late eighties, and the other, a 65-year-old woman, was reported this week in Science. Both experienced bleeding in the brain, a known side effect of certain types of anti-amyloid drugs, and both had also taken blood thinners.

Eisai said the deaths were not due to the drug because “both cases had significant comorbidities and risk factors including anticoagulation contributing to macrohaemorrhage or death."

Still, the drug did cause brain swelling and bleeding in some people who received the drug in its trial phase, a side effect that can mostly be managed, but will surely be weighed by physicians and their patients. And the risk associated with taking blood thinners could further complicate who will be eligible to take lecanemab.

None of this means lecanemab won’t be worthwhile for some patients of this feared disease marked by losses of memory. But there’s still much work to be done on understanding for whom it will be a good fit and what that would mean in the daily lives of patients. By showing that getting rid of amyloid can alter the course of Alzheimer’s, lecanemab is a sure scientific breakthrough. But its therapeutic impact is what matters most in this case.

Lisa Jarvis is a Bloomberg Opinion columnist covering biotech, health care and the pharmaceutical industry.

 

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout